Sign up today for an exclusive discount along with our 30-day GUARANTEE — Love us or leave, with your money back! Click here to become a part of our growing community and learn how to stop gambling with your investments. We will teach you to BE THE HOUSE — Not the Gambler!

Click here to see some testimonials from our members!

Wedbush Likes Voyager's Gene Therapy Pipeline, Initiates At Outperform

Courtesy of Benzinga.

Wedbush Likes Voyager's Gene Therapy Pipeline, Initiates At Outperform

Related VYGR
4 New Issues Make Today The Hottest IPO Day In Months
IPOs Expected for Nov. 11, '15: WVE, EQBK, AAAP, VYGR

  • Shares of Voyager Therapeutics Inc (NASDAQ: VYGR) have appreciated 64.79 percent over the past month, with the share price almost at the 52-week high on December 4.
  • Wedbush’s David M. Nierengarten initiated coverage of the company with an Outperform rating and price target of $36.
  • The company is pioneering in AAV-based gene therapy for serious disorders of the central nervous system, which Nierengarten believes is an “ideal site” for gene therapy.
  • Analyst David Nierengarten explained that Voyager Therapeutics has selected various Central Nervous System (CNS) diseases, “with validated, specific gene targets that are amenable to AAV gene therapy.”

    The CNS is an “ideal site for gene therapy due to its “immune privilege” status and terminally-differentiated cells that allow long-term transgene expression,” Nierengarten went on to say.

    VY-AADC01 And Parkinson’s

    The company’s lead program, VY-AADC01, is currently being development for the treatment of advanced Parkinson’s disease. The drug aims to restore the expression of an enzyme, AADC, which is responsible for converting L-Dopa to Dopamine, but is progressively lost due to Parkinson’s.

    Therefore, by restoring AADC levels, the drug is expected to help with significant improvement in motor skills, as well as L-Dopa responsiveness.

    Related Link: Piper Jaffray Initiates Coverage On Voyager therapeutics At Overweight

    VY-SOD101 And ALS

    The second pipeline drug is VY-SOD101, which is gene therapy for the treatment of ALS or monogenic amyotrophic lateral sclerosis. “VYGR’s other preclinical programs target Friedreich’s ataxia, Huntington’s disease and spinal muscular atrophy,” Nierengarten added.

    According to the Wedbush report, Voyager Therapeutics’ pipeline products are backed by robust preclinical data.

    Partnerships Boost Benefits

    In addition, the company’s strategic partnership with Genzyme not only “validates VYGR’s product development platform,” but also “allows leverage of the combined expertise, and provides substantial financial support for VYGR to develop its pipeline,” the report said.

    Image Credit: Public Domain

    Latest Ratings for VYGR

    Date Firm Action From To
    Dec 2015 Piper Jaffray Initiates Coverage on Overweight
    Dec 2015 Cowen & Company Initiates Coverage on Outperform
    Dec 2015 Wedbush Initiates Coverage on Outperform

    View More Analyst Ratings for VYGR
    View the Latest Analyst Ratings

    Posted-In: Analyst Color Biotech Long Ideas Health Care Initiation Top Stories Analyst Ratings Trading Ideas Best of Benzinga


    Do you know someone who would benefit from this information? We can send your friend a strictly confidential, one-time email telling them about this information. Your privacy and your friend's privacy is your business... no spam! Click here and tell a friend!





    You must be logged in to make a comment.
    You can sign up for a membership or get a FREE Daily News membership or log in

    Sign up today for an exclusive discount along with our 30-day GUARANTEE — Love us or leave, with your money back! Click here to become a part of our growing community and learn how to stop gambling with your investments. We will teach you to BE THE HOUSE — Not the Gambler!

    Click here to see some testimonials from our members!